Biomarkers Predict Prognosis for Patients With mCRPCPatrice Olson
Published Online: Thursday, October 3, 2013
"Howard Scher, MD, chief of Genitourinary Oncology Services at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering Cancer Center, in Manhattan, presented the findings during the 2013 European Cancer Congress..
...Based on individual risk assessment of 711 patients at the 12-week post-treatment mark in the COU-AA-30 trial,
“the probability of being alive at 2 years was 46% for patients in a good risk category, while if patients were in a high-risk category at the same time point, the probability of being alive was 2%,”Scher said in an interview.
...
“We would argue that if patients are still in a high-risk category at the 12-week point, physicians should consider doing something else......Patients were categorized as high-risk if they had 5 or more CTCs and LDH >250 IU/L; intermediate-risk if the numbers of CTCs were ≥5 but LDH was ≤250 IU/L; and low-risk with a CTC count of ≤4 and normal LDH levels...
...
“In other words, the drug has done what it’s going to do by 12 weeks, and you are now in either a high-risk or a low-risk category, and treatment no longer influences that difference in risk. And we were able to satisfy criterion 4, as well.”
...Last—and the most difficult criterion to satisfy—was that the biomarker needed to capture the treatment effect on survival..."
www.onclive.com/conference-coverage/ecco-esmo-2013/Biomarkers-Predict-Prognosis-for-Patients-With-mCRPCAlso There is interesting Abstract about
Zytiga in ECCO 2013 Congress:
Dose intensity of abiraterone acetate and administration of post-abiraterone chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) - a real world analysisG. Sonpavde, K. Tangirala, J. Mehta, J. Sung, L. Nicacio, R. Dhawan
"Results: Median age was 72 years.
Median number of monthly AA refills was 4. MPR was similar in post-D (0.69) and pre-D (0.67) group.
In pre-D setting, 421 patients initiated AA of which 137 (32.5%) discontinued AA within 3 months and 244 (58%) discontinued within 6 months. In post-D setting, 313 patients initiated AA of which 94 (30%) discontinued within 3 months and 118 (60.1%) discontinued within 6 months. In the evaluable pre-D group (N=74), use of D and/or C post-AA occurred in 31.1% of patients. In the evaluable post-D group (N=34), 44% of patients received D and/or C post-AA.
Conclusion: The observed persistence and dose intensity of AA for mCRPC patients in a real world setting suggest that better patient selection is warranted to address disease and patient heterogeneity and examination of factors responsible for suboptimal adherence may be important. The rate of post-AA chemotherapy with D and/or C appears low..."